Abstract
The tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early-phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early-phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need.
Highlights
Experts provided a framework to translate therapeutics (discovery to clinical trials).
Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial).
Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics)
Tau therapeutics are being tested in Alzheimer’s disease; primary tauopathies have a large unmet need.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Howard H. Feldman,
Jeffrey L. Cummings,
Adam L. Boxer,
Adam M. Staffaroni,
David S. Knopman,
Stacey J. Sukoff Rizzo,
Paul R. Territo,
Steven E. Arnold,
Clive Ballard,
Dirk Beher,
Bradley F. Boeve,
Penny A. Dacks,
Kristophe Diaz,
Colin Ewen,
Brian Fiske,
M. Isabel Gonzalez,
Glenn A. Harris,
Beth J. Hoffman,
Terina N. Martinez,
Eric McDade,
Laura K. Nisenbaum,
Jose‐Alberto Palma,
Melanie Quintana,
Gil D. Rabinovici,
Jonathan D. Rohrer,
Howard J. Rosen,
Matthew D. Troyer,
Doo Yeon Kim,
Rudolph E. Tanzi,
Henrik Zetterberg,
Nick K. Ziogas,
Patrick C. May,
Amy Rommel | September 24, 2024